LEADER 04096nam  2201153z- 450 
001 9910557525903321
005 20231214133353.0
035   $a(CKB)5400000000044319
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69086
035   $a(EXLCZ)995400000000044319
100   $a20202105d2020      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aVirus-Like Particle Vaccines
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 electronic resource (262 p.)
311   $a3-03943-074-2 
311   $a3-03943-075-0 
330   $aThe structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.
606   $aHumanities$2bicssc
606   $aSocial interaction$2bicssc
610   $avirus-like particle
610   $ainfluenza A(H1N1)pdm09
610   $avaccination
610   $apregnant women
610   $aantibody titers
610   $anorovirus
610   $aVLP
610   $avaccine
610   $agenotype
610   $apre-existing immunity
610   $across-reactivity
610   $ablocking antibodies
610   $aoriginal antigenic sin (OAS)
610   $aHPVs
610   $avaccines
610   $avirus-like particles (VLPs)
610   $aminor capsid protein (L2)
610   $aHCMV
610   $acytomegalovirus
610   $ananoparticle
610   $aimmune response
610   $aSudan virus
610   $amice
610   $ahorse
610   $apurified IgG
610   $along-lived plasma cells
610   $aantibodies
610   $amultivalency
610   $avirus-like particles
610   $aantigenic analysis
610   $aepitope characterization
610   $ahepatitis E vaccine
610   $aserological evaluation
610   $avirion-like epitopes
610   $awell-characterized vaccines
610   $ahepatitis B virus
610   $asurface (envelope) antigen
610   $asub-viral particle
610   $acapsid
610   $aantigen display
610   $aplatform
610   $aviral quantification
610   $aNTA
610   $aflow virometry
610   $aSRFM
610   $acryo-TEM
610   $aSEM
610   $aplant virus
610   $avirus-like
610   $avaccine platform
610   $aepitope
610   $aantigen
610   $acat allergy
610   $aFel d 1
610   $aHypoCat?
610   $aIL-13
610   $ainterleukin-13
610   $aTfh cells
610   $acancer
610   $aimmunotherapy
610   $aH7N9
610   $apandemic influenza A
610   $aavian flu
610   $aIAV
610   $aVLP vaccine
615  7$aHumanities
615  7$aSocial interaction
700   $aBachmann$b Martin F$4edt$01322916
702   $aVogel$b Monique$4edt
702   $aBachmann$b Martin F$4oth
702   $aVogel$b Monique$4oth
906   $aBOOK
912   $a9910557525903321
996   $aVirus-Like Particle Vaccines$93035261
997   $aUNINA